Skip to main content
SpringerLink
Log in

Do primary prevention benefits of statins outweigh diabetes risk?

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ.Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380: 565-571, 11 Aug 2012. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(12)61190-8

  2. Watts GF, Ooi EM.Balancing the cardiometabolic benefits and risks of statins. Lancet 380: 541-543, 11 Aug 2012. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(12)61301-4

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Do primary prevention benefits of statins outweigh diabetes risk?. React. Wkly. 1415, 3 (2012). https://doi.org/10.2165/00128415-201214150-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214150-00006

Keywords

Search

Navigation